J clin oncol 2005 23 6549-55

Author: ikxm

August undefined, 2024

WebJan 28, 2024 · J Am Geriatr Soc 2007; 55: 993–1000. 21. Jang RW, Burman D, Swami N et al. Impact of an oncology palliative care clinic on access to home care services. Am J Hosp Palliat Care 2013; 30: 425–431. ... J Clin Oncol 2005; 23: 6865–6872. 24. Yoong J, Park ER, Greer JA et al. Early palliative care in advanced lung cancer: a qualitative study ... WebApr 8, 2024 · 55. Headley JA, Ownby KK, John Lauri D. The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. Oncol Nurs Forum 2004; 31(5): 977–983. Crossref. PubMed. ... J Clin Oncol 2005; 23(4): 899–909. Crossref. PubMed. ISI. Google Scholar. 59.

Exercise interventions for advanced cancer palliative care …

WebJ Clin Oncol. 2005;23(3):609–618. 14. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. ... :52–55. 42. Patel JN. Cancer … WebSearch worldwide, life-sciences literature Search. Advanced Search Coronavirus articles and preprints Search examples: "breast cancer" Smith J hawkish policy meaning

Frontiers Relapsed and refractory yolk sac tumor of the …

WebApr 25, 2012 · XmAb2513 is a modified anti-CD30 antibody with increased binding affinity to the Fc receptor. In vitro data showed more potent and efficacious cell killing than first-generation anti-CD30 monoclonal antibodies XDA-060 and SGN-30. In clinical trials, only phase I data are available. WebAug 17, 2024 · J Clin Oncol. 2005 Dec 20. 23(36):9290-4. [QxMD MEDLINE Link] . Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J. Combination of paclitaxel, ifosfamide, and cisplatin is an... WebMar 30, 2024 · J Clin Oncol. 2008; 26:848–55. [Google Scholar] 12. ... J Clin Oncol. 2005; 23:190–6. [Google Scholar] 13. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012; 30:1030–3. [Google Scholar] 14. Gajra A, Klepin HD, Feng T, et al. Predictors of chemotherapy dose reduction at first cycle in ... boston medical center volunteering

Seminoma Testicular Cancer Treatment Protocols

Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective …

WebJul 20, 2005 · 10.1200/JCO.2005.07.757 Abstract Purpose: To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and methods: WebJan 1, 2009 · Request PDF On Jan 1, 2009, J.S. Parker and others published J Clin Oncol. Find, read and cite all the research you need on ResearchGate hawkish policy meansWebAug 20, 2005 · The most common toxicities were anemia, acne-like skin rash, leukopenia, fatigue and malaise, and nausea and vomiting. Seven patients (5%) developed a grade 3 … hawkish outlook meaning

"WebAug 9, 2024 · 42. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol (2005) 23(27):6549–55. doi: 10.1200/JCO.2005.19.638. PubMed Abstract CrossRef Full Text Google Scholar " - J clin oncol 2005 23 6549-55

J clin oncol 2005 23 6549-55

WebOct 24, 2024 · J Clin Oncol. 1998;16(7):2500-4. Kondagunta GV et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549-55.

Did you know?

WebFeb 20, 2024 · Favorable responses were achieved by 80%, with complete responses in 23 patients (77%) and a partial response with marker normalization in one patient. At a median follow-up of 33 months, 22 (73%) of the favorable … WebSep 21, 2016 · Patients eligible to participate in the phase III study had histologically confirmed, bidimensionally measurable, metastatic CRC. Patients had to be at least 18 years old, have an Eastern Cooperative Oncology Group (ECOG) performance status 13 of 0 or 1, have a life expectancy greater than 3 months, and have adequate hematologic, hepatic, …

WebNov 20, 2014 · Masses larger than 3 cm carry a higher risk of containing seminoma, and positron-emission tomographic imaging is sometimes performed 6 weeks after … WebJan 29, 2014 · J Clin Oncol. 2005. 23:6549-55. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin …

WebJ Clin Oncol. 2005 Sep 20;23(27):6549-55. link to original article contains dosing details in manuscript PubMed; Kurobe M, Kawai K, Oikawa T, Ichioka D, Kandori S, Takaoka E, Kojima T, Joraku A, Suetomi T, Miyazaki J, Nishiyama H. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor. ... WebMar 5, 2014 · We did this phase 3 randomised controlled trial (EORTC 62012) at 38 hospitals in ten countries. We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarcoma, age 18–60 years with a WHO performance status of 0 or 1.

WebJun 26, 2024 · J Clin Oncol. 2005;23(27):6549–55. Article CAS PubMed Google Scholar Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bouzy J, Droz JP, Biron P, Genito-Urinary Group of the French Federation of Cancer Centers (GETUG-FNCLCC, European …

WebIntroduction. In China and all around the world, lung cancer remains the most common cause of death in cancer patients. 1 Of all lung cancers, non-small cell lung cancer (NSCLC), as a subclass, accounts for about 80–85% of the total incidence. 2 Adenocarcinoma is currently the predominant histological subtype of NSCLC. 3,4 The reported average 5-year … boston medical center zoom loginWebMay 28, 2024 · J Clin Oncol (2005) 23:6549–55. doi: 10.1200/JCO.2005.19.638. PubMed Abstract CrossRef Full Text Google Scholar. 33. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic … hawkish pivotWebApr 20, 2005 · 10.1200/JCO.2005.09.050 Abstract Purpose: This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy. Patients and methods: boston medical center wrap programWebSep 21, 2016 · Journal of Clinical Oncology > List of Issues > Volume 23, Issue 27 > Genitourinary Cancer OPTIONS & TOOLS Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors G. Varuni Kondagunta , Jennifer Bacik , Alessia Donadio , Dean Bajorin , … boston medical center wound care clinicWebJan 29, 2024 · J Clin Oncol. 2005. 23:6549-55. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J … boston medical health net loginWebPubMed boston medical group cnpjWebIntroduction. Multiple myeloma is a hematological malignancy characterized by neoplastic proliferation of clonal plasma cells. 1 Several landmark advances have been made in the … boston medical center yawkey pharmacy